SCHEMBL20068087

SCHEMBL20068087

CC(C)C1=CNCN(C2CCCC2)C1=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 1/20 0.33
ALDH1A1 P00352 3/20 0.33
NPC1 O15118 1/20 0.33
TSHR P16473 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
JAK2 O60674 2/20 0.32
JAK1 P23458 2/20 0.32
TYK2 P29597 2/20 0.32
JAK3 P52333 2/20 0.32
MCOLN3 Q8TDD5 1/20 0.32
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HSD11B1 P28845 2/20 0.31
MAPK1 P28482 1/20 0.31
POLB P06746 1/20 0.31
PARP1 P09874 1/20 0.31
HTT P42858 1/20 0.31
ESR2 Q92731 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20061296 0.69 ALDH1A1 (0.33) ALDH1A1JAK2JAK1TYK2JAK3
SCHEMBL8824677 0.65 JAK2 (0.40) ALDH1A1KMT2AJAK2JAK1TYK2
SCHEMBL18332828 0.65 CYP2C9 (0.33) ALDH1A1GAA
SCHEMBL11808256 0.64 JAK2 (0.42) ALDH1A1KMT2AJAK2JAK1TYK2
SCHEMBL20061275 0.61
SCHEMBL22414319 0.58 CYP2C19 (0.38) ALDH1A1GAAHSD11B1MAPK1POLB
SCHEMBL22414318 0.58 CYP2C19 (0.38) ALDH1A1GAAHSD11B1MAPK1POLB
SCHEMBL17704768 0.58 POLB (0.42) GAAHSD11B1POLBPARP1HTT
SCHEMBL13384535 0.57 SMN1; SMN2 (0.38) ALDH1A1NPC1RAB9AMCOLN3HPGD
SCHEMBL6925075 0.57 ALDH1A1 (0.49) ALDH1A1NPC1TSHRKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180105527-A1 HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180105527-A1 HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT WEE2, WEE1, ITK CDK4 1299/4885ALDH1A1 3247/4885NPC1 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.